BiotechTube

Nalmefene + Placebo

Phase 2Recruiting
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pruritus

Conditions

Pruritus, Primary Biliary Cholangitis

Trial Timeline

Jun 1, 2026 → Jun 1, 2027

NCT ID
NCT06733519

About Nalmefene + Placebo

Nalmefene + Placebo is a phase 2 stage product being developed by Tharimmune for Pruritus. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06733519. Target conditions include Pruritus, Primary Biliary Cholangitis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06733519Phase 2Recruiting

Competing Products

20 competing products in Pruritus

See all competitors
ProductCompanyStageHype Score
SHR0410Jiangsu Hengrui MedicinePhase 1
33
SHR0410 + PlaceboJiangsu Hengrui MedicinePhase 1
33
DNK333 5 mg + Placebo to 5 mg + DNK333 25 mg + Placebo to 25 mg + DNK333 100 mg + Placebo to 100 mg + Betamethasone 4 mg + DNK333 1mg + Placebo to 1mgNovartisPhase 2
52
MR13A9 + PlaceboKissei PharmaceuticalPhase 3
76
MR13A9 + PlaceboKissei PharmaceuticalPhase 2
51
GabapentinPfizerPre-clinical
22
Dupilumab + Placebo + Fexofenadine (loratadine if not available)SanofiPhase 3
76
BLU-5937 + PlaceboGSK plcPhase 2
51
Dupilumab 300Mg Solution for InjectionRegeneron PharmaceuticalsPhase 2
51
REGN846Regeneron PharmaceuticalsPhase 1/2
40
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 2
49
Stage I:HSK21542 0.05 μg/kg + Stage I:HSK21542 0.15 μg/kg + Stage I:HSK21542 0.30 μg/kg + Stage I:HSK21542 0.80 μg/kg + Stage II:HSK21542 0.3 μg/kg + Stage II:HSK21542 0.6 μg/kgHaisco Pharmaceutical GroupPhase 2
49
HSK21542 tablet + PlaceboHaisco Pharmaceutical GroupPhase 2
49
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
74
nalbuphine HCl ERTrevi TherapeuticsPhase 2/3
60
Nalbuphine HCL ERTrevi TherapeuticsPhase 1
28
nalbuphine HCl ER tablets 60 mg BID + nalbuphine HCl ER tablets 120mg BID + Placebo tablets BIDTrevi TherapeuticsPhase 2/3
60
VLY-686 + PlaceboVanda PharmaceuticalsPhase 2
44
VLY-686 + PlaceboVanda PharmaceuticalsPhase 1
25
Serlopitant + PlaceboVyne TherapeuticsPhase 2
44

Other Products from Tharimmune

NalmefenePhase 1
25